Replies to post #18356 on Aytu BioScience Inc. (AYTU)

[SoCalDreamer72]

I expect them to shatter what Bezinga is touting! They should do 11-12 million without selling one test! I believe they did 8 million with only part of INNV sales. If they add a full quarter of INNV with Natesto and sold zero tests they’d probably sell more than 12. Add the tests and we’re talking much more than 11-12!

[Drugdoctor]

Official NT 10-K is filed....

PART II — RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)



(a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;


?

(b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
(c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
PART III — NARRATIVE

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.



Aytu BioScience, Inc. (the “Company”) is filing this Form 12b-25 with the Securities and Exchange Commission (the “Commission”) to postpone the filing of its Annual Report on Form 10-K for the annual period ended June 30, 2020 (the “Form 10-K”) beyond September 28, 2020, the prescribed due date for such filing. The postponement allows for additional time to finalize financial statements due to the additional workload created by the recently completed acquisition of Innovus Pharmaceuticals (the "Innovus Merger") and the Cerecor, Inc. pediatric prescription portfolio (the "Pediatric Portfolio") and to accommodate scheduling needs related to COVID-19. The Company expects to file the Form 10-K with the Commission no later than fifteen calendar days after the original prescribed date, as permitted by Rule 12b-25.

https://ih.advfn.com/stock-market/NASDAQ/aytu-bioscience-AYTU/stock-news/83346757/notification-that-annual-report-will-be-submitted